Search research articles
Contact Us
Filters
Showing results (151-160 of 169) with videos related to
Page
of 17
Sort By:
The New England Journal of Medicine
|
May 7, 2019
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, et al.
American Journal of Human Genetics
|
January 31, 2017
Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis
Markus Riessland, Anna Kaczmarek, Svenja Schneider, et al.
JCI Insight
|
March 8, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease
Tracy A Cole, Hien Zhao, Timothy J Collier, et al.
Biorxiv : the Preprint Server for Biology
|
November 22, 2024
Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding
Ella W Mathews, Sydney R Coffey, Annette Gärtner, et al.
Science (New York, N.Y.)
|
March 17, 2023
Mechanism of <i>STMN2</i> cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies
Michael W Baughn, Ze'ev Melamed, Jone López-Erauskin, et al.
Nature Reviews. Drug Discovery
|
February 26, 2024
Opportunities and challenges for innovative and equitable healthcare
David J Ecker, Clarice D Aiello, Joseph R Arron, et al.
Nature Communications
|
November 14, 2025
Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding
Ella W Mathews, Sydney R Coffey, Annette Gärtner, et al.
Neuron
|
October 25, 2016
Protein-RNA Networks Regulated by Normal and ALS-Associated Mutant HNRNPA2B1 in the Nervous System
Fernando J Martinez, Gabriel A Pratt, Eric L Van Nostrand, et al.
Nature Neuroscience
|
November 23, 2023
Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation
Jone López-Erauskin, Mariana Bravo-Hernandez, Maximiliano Presa, et al.
The Lancet. Neurology
|
February 21, 2023
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
Charles A Thornton, Richard Thomas Moxley, Katy Eichinger, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 169) with videos related to
Sort By:
Page
of 17
The New England Journal of Medicine
|
May 7, 2019
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, et al.
American Journal of Human Genetics
|
January 31, 2017
Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis
Markus Riessland, Anna Kaczmarek, Svenja Schneider, et al.
JCI Insight
|
March 8, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease
Tracy A Cole, Hien Zhao, Timothy J Collier, et al.
Biorxiv : the Preprint Server for Biology
|
November 22, 2024
Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding
Ella W Mathews, Sydney R Coffey, Annette Gärtner, et al.
Science (New York, N.Y.)
|
March 17, 2023
Mechanism of <i>STMN2</i> cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies
Michael W Baughn, Ze'ev Melamed, Jone López-Erauskin, et al.
Nature Reviews. Drug Discovery
|
February 26, 2024
Opportunities and challenges for innovative and equitable healthcare
David J Ecker, Clarice D Aiello, Joseph R Arron, et al.
Nature Communications
|
November 14, 2025
Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding
Ella W Mathews, Sydney R Coffey, Annette Gärtner, et al.
Neuron
|
October 25, 2016
Protein-RNA Networks Regulated by Normal and ALS-Associated Mutant HNRNPA2B1 in the Nervous System
Fernando J Martinez, Gabriel A Pratt, Eric L Van Nostrand, et al.
Nature Neuroscience
|
November 23, 2023
Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation
Jone López-Erauskin, Mariana Bravo-Hernandez, Maximiliano Presa, et al.
The Lancet. Neurology
|
February 21, 2023
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
Charles A Thornton, Richard Thomas Moxley, Katy Eichinger, et al.
Page
of 17